Increasing Coverage in Mass Drug Administration for Lymphatic Filariasis Elimination in an Urban Setting: a Study of Malindi Town, Kenya

被引:39
|
作者
Njomo, Doris W. [1 ]
Mukoko, Dunstan A. [2 ]
Nyamongo, Nipher K. [1 ]
Karanja, Joan [3 ]
机构
[1] Kenya Med Res Inst KEMRI, Eastern & Southern Africa Ctr Int Parasite Contro, Nairobi, Kenya
[2] Minist Hlth, Div Vector Borne & Neglected Trop Dis, Nairobi, Kenya
[3] Minist Hlth, Malindi Dist Hosp, Malindi, Kenya
来源
PLOS ONE | 2014年 / 9卷 / 01期
基金
比尔及梅琳达.盖茨基金会;
关键词
DIETHYLCARBAMAZINE; PROGRAM; ALBENDAZOLE; IVERMECTIN; INFECTION; INDIA;
D O I
10.1371/journal.pone.0083413
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Introduction: Implementation of Mass Drug Administration (MDA) in urban settings is an obstacle to Lymphatic Filariasis (LF) elimination. No urban-specific guidelines on MDA in urban areas exist. Malindi district urban area had received 4 MDA rounds by the time the current study was implemented. Programme data showed average treatment coverage of 28.4% (2011 MDA), far below recommended minimum of 65-80%. Methods: To identify, design and test strategies for increased treatment coverage in urban areas, a quasi-experimental study was conducted in Malindi urban area. Three sub-locations with lowest treatment coverage in 2011 MDA were purposively selected. In the pre-test phase, 947 household heads sampled using systematic random method were interviewed for quantitative data. For qualitative data, 12 Focus Group Discussions (FGDs) with single sex adult and youth male and female groups and 3 with community drug distributors (CDDs) were conducted. Forty in-depth interviews with opinion leaders and self-administered questionnaires with District Public Health officers purposively selected were carried out. The quantitative data were analyzed using SPSS version 16 and statistical significance assessed by x(2) test. The qualitative data were analyzed manually according to study's themes. Results and Discussion: The identified strategies were implemented prior to and during 2012 MDA in two sub-locations (experimental) while in the third (control), usual MDA strategies were applied. In the post-test phase, 2012 MDA coverage in experimental and control sub-locations was comparatively assessed for effect of the newly designed strategies on urban MDA. Results indicated improved treatment coverage in experimental sub-locations, 77.1% in Shella and 66.0% in Barani. Central (control) sub-location also attained high coverage, 70.4% indicating average treatment coverage of 71%. Conclusion: The identified strategies contributed to increased treatment coverage in experimental sites and should be applied in urban areas. Due to closeness of sites, spillover effects may have contributed to increased coverage in the control site.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] The Role of Personal Opinions and Experiences in Compliance with Mass Drug Administration for Lymphatic Filariasis Elimination in Kenya
    Njomo, Doris W.
    Amuyunzu-Nyamongo, Mary
    Magambo, Japheth K.
    Njenga, Sammy M.
    PLOS ONE, 2012, 7 (11):
  • [2] Awareness and Coverage of Mass Drug Administration for Elimination of Lymphatic Filariasis: A Community Based Cross Sectional Study in Nepal
    Adhikari, Ram Kumar
    Sherchand, Jeevan Bahadur
    Mishra, Shiva Raj
    Ranabhat, Kamal
    Wagle, Rajendra Raj
    JOURNAL OF COMMUNITY HEALTH, 2015, 40 (01) : 34 - 40
  • [3] Safety and Tolerability of Mass Diethylcarbamazine and Albendazole Administration for the Elimination of Lymphatic Filariasis in Kenya: An Active Surveillance Study
    Khaemba, Christabel
    Barry, Abbie
    Omondi, Wyckliff P.
    Bota, Kefa
    Matendechero, Sultani
    Wandera, Cecilia
    Siyoi, Fred
    Kirui, Elvis
    Oluka, Margaret
    Nambwa, Pamela
    Gurumurthy, Parthasarathi
    Njenga, Sammy M.
    Guantai, Anastacia
    Aklillu, Eleni
    PHARMACEUTICALS, 2021, 14 (03)
  • [4] Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: A mixed method study
    Banerjee, Sitikantha
    Bandyopadhyay, Kajari
    Khan, Mubashshera F.
    Akkilagunta, Sujiv
    Selvaraj, Kalaiselvi
    Tripathy, Jaya P.
    Solanki, Ranjan
    Kushwaha, Arvind S.
    Deshmukh, Pradeep
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2019, 8 (09) : 3009 - 3014
  • [5] Socioeconomic factors associated with compliance with mass drug administration for lymphatic filariasis elimination in Kenya: Descriptive study results
    Njomo, Doris W.
    Amuyunzu-Nyamongo, M.
    Mukoko, Dunstan A.
    Magambo, Japheth K.
    Njenga, Sammy M.
    ANNALS OF TROPICAL MEDICINE AND PUBLIC HEALTH, 2012, 5 (02) : 103 - 110
  • [6] Modeling the Impact and Costs of Semiannual Mass Drug Administration for Accelerated Elimination of Lymphatic Filariasis
    Stolk, Wilma A.
    ten Bosch, Quirine A.
    de Vlas, Sake J.
    Fischer, Peter U.
    Weil, Gary J.
    Goldman, Ann S.
    PLOS NEGLECTED TROPICAL DISEASES, 2013, 7 (01):
  • [7] Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination
    Alexander, Neal D. E.
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2015, 109 (03) : 173 - 174
  • [8] Coverage and compliance to mass drug administration for lymphatic filariasis elimination in a district of Kerala, India
    Nujum, Zinia T.
    INTERNATIONAL HEALTH, 2011, 3 (01): : 22 - 26
  • [9] Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance
    Hussain, Mohammad A.
    Sitha, Ashok K.
    Swain, Subhashisa
    Kadam, Shridhar
    Pati, Sanghamitra
    INFECTIOUS DISEASES OF POVERTY, 2014, 3
  • [10] The Impact of Mass Drug Administration on Lymphatic Filariasis
    Aboagye, Isaac Frimpong
    Addison, Yvonne Abena Afadua
    JOURNAL OF TROPICAL MEDICINE, 2022, 2022